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Abstract At the termination step of protein synthesis, hydro-
lysis of the peptidyl-tRNA is jointly catalysed at the ribosome by
the termination codon and the polypeptide release factor (eRF1
in eukaryotes). eRF1 forms in vivo and in vitro a stable complex
with release factor eRF3, an eRF1-dependent and ribosome-
dependent GTPase. The role of the eRF1ceRF3 complex in
translation remains unclear. We have undertaken a systematic
analysis of the interactions between the human eRF1 and eRF3
employing a yeast two-hybrid assay. We show that the N-
terminal parts of eRF1 (positions 1^280) and of eRF3 (positions
1^477) are either not involved or non-essential for binding. Two
regions in each factor are critical for mutual binding: positions
478^530 and 628^637 of eRF3 and positions 281^305 and 411^
415 of eRF1. The GTP binding domain of eRF3 is not involved in
complex formation with eRF1. The GILRY pentamer (positions
411^415) conserved in eukaryotes and archaebacteria is critical
for eRF1’s ability to stimulate eRF3 GTPase. The human eRF1
lacking 22 C-terminal amino acids remains active as a release
factor and promotes an eRF3 GTPase activity whereas C-
terminally truncated eRF3 is inactive as a GTPase.
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1. Introduction
Termination of protein synthesis proceeds on the ribosomes
and requires the presence of a termination (stop) codon in the
mRNA at the ribosomal A site and the polypeptide chain
release factor (RF) of class 1 (reviewed in [1^6]). The termi-
nation reaction leads to hydrolysis of the peptidyl-tRNA, gen-
erating a free nascent polypeptide chain and a free (un-
charged) tRNA followed by the release of these components
from the ribosome.
In eukaryotes, translational termination is governed by a
single RF which recognises all three termination codons [7].
After the structure of this factor was established it was termed
eRF1 [8]. In contrast to earlier observations [9,10] where the
termination reaction was accompanied by concomitant GTP
hydrolysis, eRF1 appeared to be able to catalyse in vitro
peptidyl-tRNA hydrolysis at a high termination codon con-
centration in the absence of GTP and other factors [8,11,12].
This apparent controversy was resolved when a second RF,
termed eRF3, was identi¢ed and shown to be an eRF1-de-
pendent and ribosome-dependent GTPase [11,12]. The initial
experiments were done with eRF3 from Xenopus laevis and
the same features were revealed later for the human eRF3
[13]. It was demonstrated that eRF1 and eRF3 bound to
each other both in vitro and in vivo [12,14,15]. The complex
is stable, even at high ionic strength, and complex formation
is accompanied by signi¢cant conformational changes of
eRF1 [13]. eRF1ceRF3 complex formation and eRF3 GTPase
activity were tightly interrelated since eRF3 GTPase activity
depended on the complex formation and eRF3 alone, even
able to bind GTP, is virtually inactive in catalysing GTP
hydrolysis on the ribosome [11].
The prokaryotic RF3 [16,17], also a GTP binding protein,
di¡ered signi¢cantly from eRF3: its GTPase activity is totally
independent of RF1/RF2 [18] and no complex formation be-
tween RF1/2 and RF3 has been revealed so far [19,20]. The
N-terminal fragment of X. laevis or human eRF3 proteins was
non-essential for complex formation, and truncated eRF3
proteins retained their GTPase- and eRF1-stimulating activ-
ities [11^13]. It was suggested for Saccharomyces cerevisiae
that eRF3/Sup35p possessed two large areas for eRF1/
Sup45p binding, one of which was located within a part of
the C-terminal domain, while the other is ascribed to the N-
terminal and middle (M) domains of the molecule [15].
To gain further insight into the role of both factors in
protein synthesis, we have analysed the molecular anatomy
of interaction between the two human eRFs. To reach the
goal, we employed a LexA-based yeast two-hybrid system as
an assay for protein-protein interaction in vivo [21,22]. There
are two major advantages of using this system. First, the
protein-protein interaction proceeds in a living cell where
the interacting macromolecules are surrounded by a huge ex-
cess of other compounds which may non-speci¢cally or spe-
ci¢cally interact with the proteins under investigation. Due to
that, the interaction revealed in two-hybrid system tolerates
all these interactions and therefore is of a highly speci¢c na-
ture. The second advantage stems from the high sensitivity of
the system. If only some of the given protein molecules bind
to each other, the system will respond to it.
The systematic application of two-hybrid strategy for both
human termination factors performed in this work allowed us
to characterise molecular anatomy of eRF1ceRF3 interaction
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in vivo and to provide new data relevant to currently sug-
gested models for eRF3 function(s).
2. Materials and methods
2.1. Plasmid constructions
pVJL12/eRF1 and pVJL11/eRF3 constructs, expressing corre-
sponding eRFs as C-terminal parts of fusion proteins with the bacte-
rial LexA DNA binding domain (LexA) and pGAD3s2x/eRF1 and
pGADGH/eRF3 constructs, expressing corresponding eRF as a C-
terminal part of the fusion proteins with the yeast GAL4 transactiva-
tion domain (GAL4AD) have been previously described [13]. N- and
C-terminal deletion mutants for both eRF3 and eRF1 were generated
by PCR ampli¢cation with Pwo polymerase (Boehringer, Mannheim)
using the primers listed in Tables 1 and 2. In addition, deletion mu-
tants were made by using the unique restriction sites within the
GAL4AD expressing constructs (Tables 1 and 2). Brie£y, the
eRF3379ÿ637, eRF32ÿ43, eRF32ÿ295, eRF32ÿ478 mutants were con-
structed by removing the SpeI-SpeI, ApaI-ApaI, XbaI-EcoRI or
DraIII-EcoRI fragments, respectively, from pGADGH/eRF3 followed
by ¢lling in, if necessary, the incompatible ends of shortened parent
constructs with Klenow DNA polymerase before ligation. The
eRF32ÿ606 mutant was obtained by subcloning the BamHI-DraI frag-
ment of pUC19/GST1-Hs [23] between the BamHI and SmaI sites of
pGADGH. To create the eRF3478ÿ637 mutant, the eRF3 cDNA was
¢rst subcloned into pGAD3s2x as follows: a 115-bp fragment between
the DraI restriction site and the stop codon was generated by PCR
using the following primers: forward, GSTDRA1, DraI site under-
lined, 5P-GCCTTGAGACCTTTAAAGACTTCCC-3P ; reverse,
GSTSAL1, SalI site underlined, 5P-AAGTCGACGTCTTTCTCTG-
GAACCA-3P. The ampli¢ed fragment was ligated with the EcoRI-
DraI fragment of pUC19/GST1-Hs between the EcoRI and XhoI sites
of pGAD3s2x. The EcoRI-DraIII fragment of the resultant
pGAD3s2x/eRF3 was thereafter removed and the ends were ¢lled in
with Klenow DNA polymerase before ligation. The eRF1228ÿ437 and
eRF11ÿ230 mutants were obtained by subcloning the BamHI-SalI or
EcoRI-BamHI fragments of the PCR-ampli¢ed eRF1 cDNA [13] into
the BamHI-SalI or EcoRI-BamHI sites of pGAD3s2x. The eRF11ÿ415
mutant was generated by subcloning of a EcoRI-Asp718 fragment of
the ampli¢ed eRF1 cDNA into the EcoRI-Asp718 sites of pUC19
followed by subcloning of the EcoRI-XbaI fragment of the resultant
construct into the EcoRI-XbaI sites of pGAD3s2x.
All PCR-ampli¢ed eRF3 deletion mutants, except the eRF3139ÿ606
mutant, were subcloned between BamHI and SalI sites into
pGADGH in-frame with GAL4AD. To generate the pGADGH/
eRF3139ÿ606 construct, BamHI-EcoRI cloning sites were used. The
eRF1271ÿ437, eRF1306ÿ437, eRF1343ÿ437 and eRF1414ÿ437 mutants were
subcloned between BamHI and XhoI sites, and the eRF12ÿ410,
eRF12ÿ391 and eRF12ÿ372 mutants were subcloned between EcoRI
and XbaI sites into pGAD3s2x in frame with GAL4AD. Struc-
ture of PCR products and preservation of open reading frames for
all constructs were con¢rmed by DNA sequencing (for details see
[24]).
A set of 5P-unidirectional deletions for eRF1 was also generated
using the Double-Stranded Nested Deletion Kit (Pharmacia Biotech)
as recommended by the manufacturer. Brie£y, pGAD3s2x/eRF1 con-
struct was incubated with exonuclease III (ExoIII) at 25‡C followed
by linearisation using SpeI and EcoRI to create nuclease-resistant and
nuclease-sensitive ends, respectively. SpeI was a ¢rst cut ¢lled in with
thionucleotides before EcoRI digestion. ExoIII-digested samples were
removed at 3.5-min time intervals, then treated with S1 nuclease and
analysed by agarose gel electrophoresis to determine the size of each
deletion. The samples of interest were recircularised using T4 DNA
ligase, pulled and used as a library of subclones with progressively
deleted eRF1 cDNA for yeast transformation.
2.2. Yeast two-hybrid analysis
Two-hybrid deletion analysis of eRF1 and eRF3 interaction was
performed using a mating procedure (for details see [25]). S. cerevisiae
strain L40 (MATa), containing two reporter genes LacZ and HIS3
downstream of the DNA binding sequence for LexA, was transformed
with the eRF1-LexBD or eRF3-LexBD fusion expression construct,
and strain AMR 70 (MATK) was transformed with the construct
expressing GAL4AD fused to one of the deletion mutants of eRF.
Transformants were selected for trp1 or leu2 complementation, respec-
tively, mated on complete medium, and double-transformed diploids
were selected on both tryptophan- and leucine-de¢cient medium. Ex-
pression of the LacZ reporter gene indicating the interaction was
followed by monitoring L-galactosidase activity with X-Gal as a sub-
strate [26]. Expression of the HIS3 reporter gene was assessed by
monitoring growth on leucine-, tryptophan- and histidine-de¢cient
medium.
Screen of the eRF1 cDNA 5P-deletion library for the shortest sub-
species interacting with eRF3 was performed according to the stand-
ard two-hybrid technique [26]. The L40 yeast reporter strain was
sequentially transformed with pVJL11/eRF3 and the cDNA library,
and the double transformants expressing interacting proteins were
selected on leucine-, tryptophan- and histidine-de¢cient medium.
The ¢lter replica method was applied using X-Gal to con¢rm the
interaction. Plasmid DNA was prepared from colonies displaying a
His/LacZ phenotype and the insertion size within pGAD3s2X was
determined by PCR with pGAD-speci¢c primers. The pGAD3s2x
plasmids containing the smallest insertions were recovered using
HB101 as a recipient strain, selected on leucine-de¢cient M9 medium,
and the inserts were sequenced.
2.3. Expression and puri¢cation of truncated eRF1 and eRF3 proteins
In order to express eRF1 and eRF3 truncated proteins, PCR-gen-
erated products were subcloned into pQE expression vectors (Qiagen)
in frame with 6UHis tag placed at the N-terminus of the resultant
recombinant proteins. eRF3 and eRF1 deletion mutants were sub-
cloned into pQE-31 and pQE-30, respectively, between the BamHI
and SalI sites except for the eRF12ÿ410 mutant where the Asp718
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Table 1
PCR primers and restriction sites used to generate eRF3 deletion mutants for yeast two-hybrid analysis
Mutant Forward primer or 5P-restriction site Reverse primer or 3P-restriction site
eRF3379ÿ637 SpeI BamHI
eRF3471ÿ637 5P-AAGGATCCTGTGATGATGCCAAACAAG-3P 5P-TTGTCGACTTAGTCTTTCTCTGGAACC-3P
eRF3478ÿ637 DraIII BamHI
eRF3531ÿ637 5P-AAGGATCCATTTGATGCCCAGATAGTG-3P 5P-TTGTCGACTTAGTCTTTCTCTGGAACC-3P
eRF3601ÿ637 5P-AAGGATCCCATCTGCCTTGAGACCTT-3P 5P-TTGTCGACTTAGTCTTTCTCTGGAACC-3P
eRF32ÿ43 BamHI ApaI
eRF32ÿ295 BamHI XbaI
eRF32ÿ478 BamHI DraIII
eRF32ÿ606 BamHI DraI
eRF3139ÿ617 5P-AAGGATCCCATGGAACTTTCAGAACCTAT-3P 5P-TTGTCGACTTATAAGGTGAAACGACCCAT-3P
eRF3139ÿ627 5P-AAGGATCCCATGGAACTTTCAGAACCTAT-3P 5P-TTGTCGACCTATCCAATTGCAATGGTCTT-3P
eRF3139ÿ606 5P-AAGGATCCCATGGAACTTTCAGAACCTAT-3P 5P-ATATGAATTCTTAAAAGGTCTCAAGGCAGATG-3P
eRF3471ÿ617 5P-AAGGATCCTGTGATGATGCCAAACAAG-3P 5P-TTGTCGACTTATAAGGTGAAACGACCCAT-3P
eRF3471ÿ627 5P-AAGGATCCTGTGATGATGCCAAACAAG-3P 5P-TTGTCGACCTATCCAATTGCAATGGTCTT-3P
Superscript numbers in mutants indicate positions of retained amino acids.
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and PstI cloning sites of pQE-30 were used. To generate the
eRF3139ÿ478 mutant, the DraIII-SalI fragment from the pQE31/
eRF3139ÿ627 construct was removed followed by ¢lling in the ends
with Klenow DNA polymerase and ligation. For expression of the
truncated cDNA encoding eRF1 terminated at Tyr-415, a TB3-1
cDNA [27] encoding full-length eRF1 [8] was ampli¢ed by PCR
with Pwo DNA polymerase and the following oligonucleotides as
primers: forward primer KpnI (underlined), 5P-GCGGTACCGAT-
GACGATGACAAAATGGCGGACGACGACCCCAGT-3P and re-
verse primer, 5P-CGACTACCTAGTAGTCATC-3P, which is comple-
mentary to the nucleotide positions from +1301 to +1319 in TB3-1/
eRF1 cDNA [27]. The resulting ampli¢ed PCR product was gel-puri-
¢ed, digested with KpnI (KpnI sites are in the forward primer and in
the +1248 nucleotide position in TB3-1/eRF1 cDNA) and inserted
into the KpnI site of expression vector pQE-30. The expressed trun-
cated protein, designated eRF11ÿ415*, contained at the C-terminus
after Tyr-415 an additional eight amino acids (PGSTCSQA) encoded
in pQE-30 polylinker. Cells of Escherichia coli strain M15 [pREP4]
were transformed with recombinant pQE-30 or pQE-31 with cDNA
inserts encoding truncated forms of eRF1 or eRF3. The puri¢cation
of truncated forms of eRF1 and eRF3 proteins containing His tags
was performed on a Ni-NTA-agarose (Super£ow, Qiagen) column as
described [13].
2.4. In vitro assays
The eRF1 activity was measured according to Tate and Caskey [28]
with some modi¢cations [8,13]. Rabbit reticulocyte ribosomal sub-
units were isolated as described [11,13]. The expression of full-length
human eRF1 and eRF3 proteins in baculovirus system and their pu-
ri¢cation have been described [13]. eRF3 GTPase activity was fol-
lowed by accumulation of [K-32P]GDP after hydrolysis of [K-32P]GTP
using thin-layer chromatography on PEI-cellulose-coated plates (Ma-
cherey-Nagel) as described [11,13].
3. Results
3.1. Localisation of regions essential for binding of eRF3 and
eRF1
In order to delineate the regions of the human eRF3 and
eRF1 involved in complex formation in vivo, the binding of
various truncated proteins was tested using the two-hybrid
approach. AMR 70 yeast cells were transformed with plas-
mids expressing GAL4AD fused with eRF3 or eRF1 sequen-
ces, progressively deleted from either the N- or the C-terminus
(Tables 1 and 2) and then mated with L40 yeast cells express-
ing full-length eRF1 or eRF3 fused to LexA (see Section 2).
The resultant diploid yeast cells were tested for the expression
of the two distinct reporter genes, HIS3 and LacZ, to visualise
eRF1 and eRF3 interaction. The results with these reporter
genes were completely coincident: in no case did we observe
any disagreement between the two assays for the given mu-
tant. The di¡erence between the binding and non-binding
mutants (Fig. 1) for eRF1 and eRF3 in both assays was
well de¢ned: for non-binders, loss of yeast cell growth in
the HIS3 reporter assay and the absence of blue colour for
the X-Gal assay. The binding e⁄ciency of interacting mutants
to the respective partners was comparable to the interaction
between the full-length eRF1 and eRF3 as was evident from
the growth rates (HIS3 reporter) and intensity of blue colour
(LacZ reporter).
To follow intrinsic transcriptional activation capacity or
non-speci¢c binding, mating with the cells possessing an
empty vector was used. Transcriptional activation of reporter
genes driven by interaction between full-length eRF1 and
eRF3 [13] or by Ral and RLIP proteins [24] was used as
controls.
The results of the analysis presented in Fig. 1A show that
the N-terminal part of eRF3, including up to 477 amino acid
residues, was non-essential for binding to eRF1. Further de-
letions from the N side abrogated the binding. None of the
eRF3 C-terminal deletion mutants was able to bind eRF1.
These results indicate that at least two regions in eRF3 span-
ning residues from 478 to 530 and from 628 to 637 seemed to
be critical for eRF3ceRF1 interaction.
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Fig. 1. Mapping of interacting regions in the human eRF1 and
eRF3 using the yeast two-hybrid deletion analysis. Various DNA
fragments encoding truncated eRF3 or eRF1 were cloned into the
two-hybrid vectors pGADGH or pGAD3s2x, respectively, and the
resultant plasmids were transformed into AMR 70 yeast cells mated
with reporter yeast L40 cells transformed with pVJL12/eRF1 or
pVJL11/eRF3. Diploids were replicated onto triple-selective leucine-,
tryptophan- and histidine-de¢cient DO medium and/or on Whatman
paper (No. 40) laid over DO medium lacking leucine and trypto-
phan to visualise L-galactosidase activity. Schematic representation
of eRF3 (A) and eRF1 (B) deletion mutants used for the analysis.
Boxes indicate the remaining amino acid sequences. The ability of
various mutants to interact with the other factor, as follows from
the expression of both reporter genes, is indicated on the right.
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To map the eRF1 binding regions involved in the interac-
tion with eRF3, the N- and C-terminally truncated forms of
eRF1 (Fig. 1B) were tested in the same experimental set-up as
described above. In this case L40 cells were transformed with
full-length eRF3 fused to LexA and mated with AMR 70 cells
transformed with one of the eRF1 deletion mutants fused to
GAL4AD. The results of mating experiments demonstrated
that the N-terminal part of eRF1 is non-essential for binding,
delineating the essential region for eRF3ceRF1 interaction. In
order to establish the N-terminal boundary of this region
more precisely, a set of 5P-terminally truncated eRF1 cDNA
fragments was generated with ExoIII nuclease and used to
construct an expression library which was screened for inter-
action with eRF3 (see Section 2). One hundred and ninety-
two plasmids isolated from randomly selected His/LacZ
yeast colonies were analysed for insertion sizes. Five of
them containing the shortest insertions were sequenced. The
results of sequence analyses revealed that these eRF1 cDNAs
encoded deleted products starting from amino acid positions
271, 272, 275 and 281. Among these mutants eRF1281ÿ437
represented the shortest form (Fig. 1B) still able to interact
with eRF3. Thus, one eRF1 region critical for the interaction
with eRF3 encompassed the amino acid sequence from posi-
tion 281 to 305.
Among the eRF1 C-terminal deletions, the eRF11ÿ415 and
eRF12ÿ410 mutants represented the shortest interacting and
the longest non-interacting mutant proteins, respectively
(Fig. 1B). Taken together, these results indicate that the sec-
ond eRF1 region critical for eRF3 binding encompassed only
¢ve amino acids from 411 to 415. Consequently, two regions
encompassing amino acids 281^305 and 411^415 seem to be
indispensable for the interaction with eRF3.
3.2. Functional activity of eRF1 and eRF3 mutants
Although the C-terminus of eRF3 (positions 628^637) was
critical for eRF1 binding, the C-terminus of eRF1 (positions
416^437) appeared to be non-essential (Figs. 1 and 2). To
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Fig. 3. Activity of the human eRF1 and eRF3 mutants in a GTPase
assay. Incubation mixtures (12.5 Wl) contained 5 WM [K-32P]GTP
(Amersham, speci¢c activity 5000 cpm/pmol) and, where indicated,
0.02 WM rabbit ribosomes, full-length human eRF1, or eRF3, or
their truncated forms (10 pmol each). The reaction was stopped by
addition of 1 Wl of a solution containing 20 mM EDTA and 5%
SDS. 5-Wl aliquots were spotted onto PEI-cellulose plates and re-
solved in 1 M acetic acid and 1 M LiCl during 1.5 h. The plates
were dried and exposed to Hyper¢lm-MP (Amersham). The human
eRF1 and eRF3 were expressed in the baculovirus system and puri-
¢ed [13]. The truncated eRF1 and eRF3 proteins containing the N-
terminal His tag were expressed in E. coli (see Section 2) and puri-
¢ed on Ni-NTA-agarose column [13]. The human eRF3 GTPase ac-
tivity measured in the presence of eRF1 and ribosomes was used as
a positive control. The human eRF3 lacking the N-terminal 139
amino acid residues is active as a GTPase in the presence of eRF1
and the ribosomes [13]. The residual GTPase activity detected in in-
cubation mixture without ribosomes is due to trace amounts of E.
coli GTPases remaining in the puri¢ed proteins.
Fig. 2. Critical regions for the human eRF1 and eRF3 binding in
comparison with other data. Critical binding regions, black boxes;
regions non-essential or not involved in binding, white boxes; re-
gions with unknown role in mutual binding, hatched boxes. G des-
ignates four putative GTP binding motifs. Subdivision of S. cerevi-
siae eRF3/Sup35p into three domains, N, M and C, is indicated.
Table 2
PCR primers and restriction sites used to generate eRF1 deletion mutants for yeast two-hybrid analysis
Mutant Forward primer or 5P-restriction site Reverse primer or 3P-restriction site
eRF1228ÿ437 BamHI SalI
eRF1271ÿ437 5P-TTGGATCCTCTACTGAAGTCCTCTCC-3P 5P-TTGTCGACCTAGTAGTCATCAAGGTCA-3P
eRF1306ÿ437 5P-AAGGATCCGAAGATACACTAAAGGCTTT-3P 5P-TTGTCGACCTAGTAGTCATCAAGGTCA-3P
eRF1343ÿ437 5P-AAGGATCCATTCTCTATCTAACTCCAGA-3P 5P-TTGTCGACCTAGTAGTCATCAAGGTCA-3P
eRF1414ÿ437 5P-AAGGATCCCGGTACCGAGTAGATTTC-3P 5P-TTGTCGACCTAGTAGTCATCAAGGTCA-3P
eFR11ÿ415 EcoRI Asp718
eRF12ÿ410 5P-ATATGAATTCTCGGTACCGCGGACGACCCCAGTGC-3P 5P-ATATTCTAGACTGCAGCTATCCAATTCCACCAAATCCTTT-3P
eRF12ÿ391 5P-ATATGAATTCTCGGTACCGCGGACGACCCCAGTGC-3P 5P-ATATTCTAGACTGCAGCTAAATTTCCAACGTAGCTCCAAA-3P
eRF12ÿ372 5P-ATATGAATTCTCGGTACCGCGGACGACCCCAGTGC-3P 5P-ATATTCTAGACTGCAGCTACATGCTCTCGATAAGCTCAT-3P
eRF11ÿ230 EcoRI BamHI
Superscript numbers in mutants indicate positions of retained amino acids.
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extend this observation using another approach, we measured
the functional activity of eRF1 mutants in two assay systems.
First, we showed (Fig. 3) that the C-terminally truncated
eRF11ÿ415* mutant promoted eRF3 GTPase activity in the
presence of the ribosomes. This observation implied that de-
letion of the last 22 amino acid residues of eRF1 did not
interfere with eRF1ceRF3 complex formation in vitro since
eRF3 GTPase exhibited activity only if bound to eRF1 [11].
Second, the eRF11ÿ415 mutant was also active as a release
factor (not shown) promoting hydrolysis of formylmethionyl-
tRNAf Met in the presence of the ribosomes and any of the
three stop codons. This implied that the C-terminus of
eRF1 is not only dispensable for eRF3 binding but is also
non-essential for its own catalytic activity.
The GTPase-stimulating activity of the eRF1271ÿ437 mutant
was low (Fig. 3) although it contained both critical eRF3
binding regions. The lack of a considerable portion of the
eRF1 sequence (positions 1^270) where the ribosome binding
site was thought to be located might abrogate the stable eRF1
binding to the ribosome and prevent ternary eRF1ceRF3cri-
bosome complex formation, a prerequisite for eRF3 GTPase
activity.
When the critical region at the C-terminus of eRF1 was
deleted (positions 411^415) the eRF12ÿ410 mutant not only
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Fig. 4. Amino acid sequences of eRF3 (A) and eRF1 (B) involved in mutual binding. Amino acid identities (black boldface), similarities (grey
boldface) and dissimilarities (italic) are indicated. Positions corresponding to the boundaries of the interacting regions in human factors are in
boldface. GenBank accession numbers for eRF3 are: for Homo sapiens, X17644; for Xenopus laevis, L37045; for Pichia pinus, P23637; for Sac-
charomyces cerevisiae, P05453 and P05420; for Candida albicans, AF020554; for Nicotiana tabacum, L38828; for Caenorhabditis elegans,
Z92835; for Drosophila melanogaster, U88868. GenBank accession numbers for eRF1 are: for Homo sapiens, P46055; for Mus musculus,
D87691; for Mesocricetus auratus, X81626; for Xenopus laevis, P35615; for Caenorhabditis elegans, AF016452; for Arabidopsis thaliana,
X69375; for Saccharomyces cerevisiae, X04082; for Schizosaccharomyces pombe, D63883; for Methanococcus jannaschii, Q58239; for Archaeo-
globus fulgidus, AE001020 and AE000782. ClustalW Multiple Sequence Alignment Program (version 1.7, June 1997) was applied.
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lost its eRF3 binding capacity in vivo (Fig. 1) but its stimulat-
ing activity towards eRF3 GTPase was profoundly diminished
(Fig. 3). From these observations we concluded that the eRF1
region encompassing amino acids 411^415 is essential for
eRF3 binding and for stimulating eRF3 GTPase activity.
To prove further the functional role of the C-terminal re-
gion of eRF3, the eRF3139ÿ627 mutant was tested for GTPase
activity and found to be inactive (Fig. 3). Deletion of the 138
N-terminal amino acids in this mutant did not impair its func-
tional activity [11^13]. Therefore, its inactivation was caused
by the lack of the C-terminal decamer. The second eRF3
mutant, eRF3139ÿ478, lacking both critical regions for eRF1
binding, was inactive as well (Fig. 3). In both of these eRF3
mutants the GTP binding domain was retained (Fig. 2). Con-
sequently, the abolition of eRF1 binding correlated with loss
of eRF1-dependent GTPase activity. GTPase activity of the
N-terminally truncated eRF3 proteins was not tested because
of deletion of their GTP binding motifs.
4. Discussion
4.1. Structural-functional anatomy of eRF3
Two regions are critical in the eRF3 sequence for eRF1
binding: the C-terminal decamer (positions 628^637) and
the longer stretch (positions 478^530) inside the C-terminal
domain. As is evident from the alignment (Fig. 4), positions
634^637 are non-conserved in the eRF3 family whereas the
upstream positions 628^633 are conservative. Therefore, we
deduce that for eRF1 binding the C-terminal tetramer might
be dispensable while the adjacent upstream hexamer is crit-
ically important. Positions 478^530 are composed of highly
conserved (75%) and non-conserved (25%) amino acids. Since
this stretch is relatively long we suppose that conserved resi-
dues (Fig. 4) are essential for eRF1 binding while non-con-
served amino acids are dispensable.
At the C-terminal domain of eRF3 two regions essential for
binding and the fragment between them are remote from GTP
binding motifs (Fig. 2). Hence, when eRF1 binds to eRF3, the
GTPase activation is probably mediated via a conformational
change of eRF3 induced by eRF1 binding. The non-overlap-
ping of GTP and eRF1 binding regions (Fig. 2) is in agree-
ment with earlier data [12] showing that GTP binding to
eRF3 is not a¡ected by eRF1.
Very recently the mouse genes GSPT1 and GSPT2, struc-
turally related to human eRF3, have been cloned and se-
quenced [29] although the catalytic activity of their protein
products has not been demonstrated. The GSPT1 and
GSPT2 proteins were able to form a complex with human
eRF1 in the two-hybrid assay [29] as was shown earlier for
human eRF1 and eRF3 [13]. Deletion of the C-terminal do-
main (205 amino acids) of the GSPT2 protein (presumably
mouse eRF3) caused impairment of binding capacity towards
eRF1 in full agreement with our more detailed data (Fig. 1).
It is very surprising that the highly variable and functionally
non-essential N-terminal domain of eRF3/GSPT2 a¡ected
binding with the highly conserved human eRF1.
4.2. Structural-functional anatomy of eRF1
A considerable portion of the eRF1 sequence could be de-
leted from the N-terminus without a¡ecting eRF3 binding
(Fig. 1). Furthermore, 22 C-terminal amino acids may also
be deleted without loss of the binding capacity and functional
activity (Figs. 1 and 3). On the other hand, deletion of frag-
ment 281^305 or 411^415 impairs the binding of the truncated
eRF1 to eRF3 (Fig. 2). These two critical regions are highly
conserved in the eRF1 family (Fig. 4). The 411^415 amino
acid sequence is rather hydrophobic and may interact with
hydrophobic regions in eRF3. In contrast to the 411^415 re-
gion, the 281^305 region is hydrophilic (Fig. 4) and has a
potential for electrostatic interactions with eRF3.
In addition to eRF3, eRF1 binds to a catalytic subunit of
protein phosphatase 2A both in vitro and in vivo [30]. By
deletion analysis, the PP2Ac binding domain was found to
be located between amino acid residues 338 and 381 of the
human eRF1. This region is located exactly between the two
regions critical for eRF3 binding (Fig. 2). Therefore, the C
domain of eRF1 seems to be open for protein-protein inter-
actions while the N domain looks to be more adapted for
nucleic acid-protein interactions.
Recently, the eRF1 binding sites for eRF3 were analysed
for eRF1/Sup45p from Schizosaccharomyces pombe [31]. It
was concluded that the stretch of acidic amino acids at the
C-terminus of eRF1/Sup45p is a primary binding site for
eRF3. As shown here, this region is essential neither for the
human eRF3 binding nor for the human eRF1 activity. Our
conclusion is supported by the fact that the last 11 amino
acids of the eRF1 protein family are weakly conserved (Fig.
4). The other di¡erence concerns the internal essential binding
region: in the human eRF1 it encompasses positions 281^305
while in ¢ssion yeast this region was found to be much broad-
er (positions 187^247) and displaced towards the N-terminus
(Fig. 2). Surprisingly, both internal and C-terminal regions for
eRF3 binding do not overlap in the human and S. pombe
eRF1. On the other hand, our conclusion that the 22 C-ter-
minal amino acids of the human eRF1 are non-essential for
eRF1 function in vitro is consistent with the data on in vivo
complementation of C-terminally truncated ¢ssion yeast
eRF1/Sup45p with the thermosensitive Sup45p mutant from
S. cerevisiae [31].
As is well known (see [32,33]) G proteins interact with at
least two types of proteins, GAP, a GTPase activating pro-
tein, and GEF, a guanine nucleotide exchange factor. It was
suggested earlier [11,12] that eRF1 and the ribosome may be
regarded as a composite GAP by analogy with other G pro-
teins. In prokaryotes, RF3 GTPase activity depends solely on
the ribosome, not on RF1/2 [18], and EF-Ts is a GEF for EF-
Tu. For this reason one may assume that eRF3 is also acti-
vated mostly or solely by the ribosome, and if so, eRF1 may
predominantly serve as a GEF for eRF3.
The two-hybrid system does not make it possible to detect
the complex inside the ribosomal particle. However, since
eRF3 GTPase is not only ribosome-dependent, but also
eRF1-dependent, there is little doubt that this complex is
also present on the ribosome at a certain stage of the trans-
lation cycle. It is noteworthy that GTP hydrolysis is required
for eRF3 function, not simply GTP binding [12].
The deletion analysis employed in this work was based on
truncation of both ends of the polypeptide chains of the fac-
tors and no internal deletions were introduced. Therefore, we
cannot yet decide whether the amino acid sequences between
the critical regions of each factor (positions 531^627 for eRF3
and positions 306^410 for eRF1) are essential or non-essential
for mutual binding (Fig. 2). The second issue which remained
unresolved in these studies concerns continuity of the critical
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regions of both factors. In principle, these regions may be
independent and topologically remote. Alternatively, the crit-
ical regions of each factor may neighbour each other in space
forming a single continuous composite binding site. To re-
solve this alternative one has to know the 3D structure of
each factor and of the complex. Regretfully, this information
is so far not available.
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